Clinical Trials

The purpose of this study is to evaluate the effectiveness, safety and tolerability of Amikacin for patients who have a mycobacterial lung disease that is not tuberculosis, and is difficult to treat.

The purpose of this study is to determine if Clofazimine is effective in treating patients with drug resistant non-tuberculous mycobacterial infections. 

The purpose of this extension study is to assess the safety, tolerability, and effectiveness of Liposomal Amikacin for Inhalation added to a multi-drug regimen in subjects with non-tuberculous mycobacterium lung infections due to Mycobacterium avium complex who were resistant to therapy in Study INS-212.

A study to evaluate the effectiveness of Liposomal Amikacin for Inhalation (LAI) when added to multi-drug regimen in subjects with Nontuberculous Mycobacterial (NTM) lung infection caused by Mycobacterium Avium Complex (MAC).

The purpoes of this study is to evaluate the safety of ORC-13661 and its ability to significantly mitigate or prevent hearing loss in patients being treated with intravenous (IV) amikacin.

The purpose of this study is to determine whether 2-drug therapy is non-inferior to 3-drug therapy against pulmonary mycobacterium avium complex (MAC) disease, and whether 2-drug therapy is better tolerated than 3-drug therapy.

The purpose of this study is to  evaluate Lamprene (Clofazimine) to treat non-tuberculous mycobacterial (NTM) infections.

The purpose of this study is to evaluate the effectiveness of ALIS + azithromycin (AZI) + ethambutol (ETH) compared to the empty liposome control (ELC) + AZI + ETH on patient reported respiratory symptoms at Month 13.

The purpose of this study is to evaluate the effectiveness of inhaled molgramostim, administered open-label, to adult cystic fibrosis subjects with chronic pulmonary nontuberculous mycobacterial (NTM) infection, with or without ongoing antimycobacterial guideline based combination therapy.